These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10155094)

  • 1. Care of the patient receiving ReoPro following angioplasty.
    Brezina K; Murphy M; Stonner T
    J Invasive Cardiol; 1994; 6 Suppl A():38A-42A; discussion 54A-56A. PubMed ID: 10155094
    [No Abstract]   [Full Text] [Related]  

  • 2. Post-procedural patient management: prevention and management of bleeding complications.
    Aguirre F
    J Invasive Cardiol; 1994; 6 Suppl A():34A-37A; discussion 54A-56A. PubMed ID: 10155093
    [No Abstract]   [Full Text] [Related]  

  • 3. Dosing and administration of ReoPro (c7E3 Fab).
    Tcheng JE
    J Invasive Cardiol; 1994; 6 Suppl A():29A-33A; discussion 51A-54A. PubMed ID: 10155091
    [No Abstract]   [Full Text] [Related]  

  • 4. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.
    Goldschmidt-Clermont PJ
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856
    [No Abstract]   [Full Text] [Related]  

  • 5. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
    Lincoff AM; Topol EJ
    Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004
    [No Abstract]   [Full Text] [Related]  

  • 6. [Glycoprotein IIb/IIIa antagonists].
    Hennemann A
    Med Monatsschr Pharm; 2000 Dec; 23(12):385-90. PubMed ID: 11147193
    [No Abstract]   [Full Text] [Related]  

  • 7. IIb/IIIa platelet inhibitors in the management of coronary artery disease.
    Talley JD
    J Ark Med Soc; 1996 Oct; 93(5):237-9. PubMed ID: 8908943
    [No Abstract]   [Full Text] [Related]  

  • 8. The platelet, the patient, and periprocedural infarction during percutaneous transluminal coronary angioplasty.
    Fischman DL; Savage MP
    JAMA; 1997 Aug; 278(6):518-9. PubMed ID: 9256229
    [No Abstract]   [Full Text] [Related]  

  • 9. Ischemic coronary syndromes and SVG Interventions--do 2b/3a inhibitors miss the target?
    Topaz O
    Catheter Cardiovasc Interv; 2007 Apr; 69(5):630-1. PubMed ID: 17377986
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? No.
    Ragosta M; Sarembock IJ
    J Thromb Haemost; 2004 Jan; 2(1):10-2. PubMed ID: 14717959
    [No Abstract]   [Full Text] [Related]  

  • 12. Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty.
    Gambassi G; Landolfi R; Bernabei R
    N Engl J Med; 1997 Oct; 337(17):1243-4. PubMed ID: 9340528
    [No Abstract]   [Full Text] [Related]  

  • 13. Massive pulmonary hemorrhage in a patient treated with a platelet glycoprotein IIb/IIIa inhibitor.
    Sitges M; Villa FP
    Int J Cardiol; 1997 Dec; 62(3):269-71. PubMed ID: 9476687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty.
    Khan SS; Forrester J
    N Engl J Med; 1997 Oct; 337(17):1243; author reply 1244-5. PubMed ID: 9340527
    [No Abstract]   [Full Text] [Related]  

  • 16. Minimally invasive bypass surgery.
    Dragu RE
    N Engl J Med; 2002 Dec; 347(26):2165-8; author reply 2165-8. PubMed ID: 12501850
    [No Abstract]   [Full Text] [Related]  

  • 17. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?
    Mukherjee D; Roffi M
    J Interv Cardiol; 2008 Apr; 21(2):118-21. PubMed ID: 18384343
    [No Abstract]   [Full Text] [Related]  

  • 18. Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes.
    Exaire JE; Lincoff AM
    J Thromb Haemost; 2004 Jan; 2(1):7-9. PubMed ID: 14717958
    [No Abstract]   [Full Text] [Related]  

  • 19. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary interventions.
    Gambhir DS; Mukhopadhyay S
    Indian Heart J; 2000; 52(5):524-32. PubMed ID: 11256774
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.